Key result
Rotigaptide boosts myocyte gap-junction coupling ~55 percentage points via Cx43.
Why the study?
Does the antiarrhythmic peptide rotigaptide enhance gap junction intercellular communication specifically via connexin 43 in cardiac myocytes and cell models?
Does the antiarrhythmic peptide rotigaptide enhance gap junction intercellular communication specifically via connexin 43 in cardiac myocytes and cell models?
Rotigaptide specifically targets Connexin 43 to enhance cellular coupling without altering overall protein expression, supporting its specific mechanism as a novel antiarrhythmic agent.
Rotigaptide's Cx43 effects in myocytes warrant clinical caution; leaves open translation to antiarrhythmic efficacy in vivo.
We investigated the effects of rotigaptide (ZP123), a stable hexapeptide with antiarrhythmic properties, on gap junction mediated intercellular communication in contracting rat neonatal cardiac myocytes, HL-1 cells derived from cardiac atrium and in HeLa cells transfected with cDNA encoding Cx43-GFP, Cx32-GFP, Cx26-GFP, wild-type Cx43 or wild-type Cx26. Intercellular communication was monitored before and after treatment with rotigaptide following microinjection of small fluorescent dyes (MW<1 kDa). The communication-modifying effect of rotigaptide was confined to cells expressing Cx43 since the peptide had no effect on dye transfer in HeLa cells expressing Cx32-GFP, Cx26-GFP or wild-type Cx26. In contrast, HeLa cells expressing Cx43-GFP exposed to 50 nM rotigaptide for 5 h showed a 40% increase in gap junction mediated communication. Rotigaptide (50 nM) increased intercellular dye transfer in myocytes and atrial HL-1 cells, where Cx43 is the dominant connexin. However, it caused no change in cell beating rates of cardiac myocytes. Western blot analysis showed that rotigaptide did not modify the overall level of Cx43 expression and changes in the phosphorylation status of the protein were not observed.We conclude that the effects of rotigaptide were confined to cells expressing Cx43.
No takes yet. Share an insight, caveat, or question.
Clarke et al. (2006) studied Arrhythmia (preclinical model) (n=50). Rotigaptide (ZP123) vs. Untreated control cells was evaluated on Gap junction mediated intercellular communication (percentage of cells transferring microinjected Alexa-488 dye to ≥11 neighboring cells) (p=<0.01). Rotigaptide (50 nM) increased gap junction intercellular dye transfer to ≥11 neighboring cells from 20.9% to 75.6% in cardiac myocytes, operating specifically via Connexin 43.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: